Patents by Inventor Matthew Jarpe

Matthew Jarpe has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS AND COMPOSITIONS FOR THE ADAR-MEDIATED EDITING OF ARGININOSUCCINATE LYASE (ASL)
    Publication number: 20230295614
    Abstract: The present invention relates to methods and compositions for editing an ASL polynucleotide, e.g., an ASL polynucleotide comprising a SNP associated with argininosuccinate lyase deficiency. The invention also relates to methods and compositions for treating or preventing argininosuccinate lyase deficiency in a subject.
    Type: Application
    Filed: November 14, 2022
    Publication date: September 21, 2023
    Inventors: Matthew Jarpe, Mallikarjuna Reddy Putta, Andrew Fraley
  • METHODS AND COMPOSITIONS FOR THE ADAR-MEDIATED EDITING OF LEUCINE RICH REPEAT KINASE 2 (LRRK2)
    Publication number: 20230295664
    Abstract: The present invention relates to methods and compositions for editing an LRRK2 polynucleotide, e.g., an LRRK2 polynucleotide comprising a SNP associated with Parkinson's Disease. The invention also relates to methods and compositions for treating or preventing Parkinson's Disease in a subject.
    Type: Application
    Filed: November 14, 2022
    Publication date: September 21, 2023
    Inventors: Matthew Jarpe, Mallikarjuna Reddy Putta, Andrew Fraley
  • METHODS AND COMPOSITIONS FOR THE ADAR-MEDIATED EDITING OF TRANSMEMBRANE CHANNEL-LIKE PROTEIN 1 (TMC1)
    Publication number: 20230272377
    Abstract: The present invention relates to methods and compositions for editing a TMC1 polynucleotide, e.g., a TMC1 polynucleotide comprising a SNP associated with autosomal recessive non-syndromic hearing loss. The invention also relates to methods and compositions for treating or preventing autosomal recessive non-syndromic hearing loss in a subject.
    Type: Application
    Filed: November 14, 2022
    Publication date: August 31, 2023
    Inventors: Matthew Jarpe, Mallikarjuna Reddy Putta, Andrew Fraley
  • METHODS AND COMPOSITIONS FOR THE ADAR-MEDIATED EDITING OF RETINOCHISIN 1 (RS1)
    Publication number: 20230272384
    Abstract: The present invention relates to methods and compositions for editing an RS1 polynucleotide, e.g., an RS1 polynucleotide comprising a SNP associated with X-linked retinoschisis (XLRS). The invention also relates to methods and compositions for treating or preventing XLRS in a subject.
    Type: Application
    Filed: November 14, 2022
    Publication date: August 31, 2023
    Inventors: Matthew Jarpe, Mallikarjuna Reddy Putta, Andrew Fraley
  • METHODS AND COMPOSITIONS FOR THE ADAR-MEDIATED EDITING OF METHYL-CPG BINDING PROTEIN 2 (MECP2)
    Publication number: 20230272376
    Abstract: The present invention relates to methods and compositions for editing a MECP2 polynucleotide, e.g., a MECP2 polynucleotide comprising a SNP associated with Rett syndrome. The invention also relates to methods and compositions for treating or preventing Rett syndrome in a subject.
    Type: Application
    Filed: November 14, 2022
    Publication date: August 31, 2023
    Inventors: Matthew Jarpe, Mallikarjuna Reddy Putta, Andrew Fraley
  • METHODS AND COMPOSITIONS FOR THE ADAR-MEDIATED EDITING OF GAP JUNCTION PROTEIN BETA 2 (GJB2)
    Publication number: 20230272383
    Abstract: The present invention relates to methods and compositions for editing a GJB2 polynucleotide, e.g., a GJB2 polynucleotide comprising a SNP associated with autosomal recessive non-syndromic hearing loss. The invention also relates to methods and compositions for treating or preventing autosomal recessive non-syndromic hearing loss in a subject.
    Type: Application
    Filed: November 14, 2022
    Publication date: August 31, 2023
    Inventors: Matthew Jarpe, Mallikarjuna Reddy Putta, Andrew Fraley
  • METHODS AND COMPOSITIONS FOR THE ADAR-MEDIATED EDITING OF ARGININOSUCCINATE SYNTHETASE (ASS1)
    Publication number: 20230257752
    Abstract: The present invention relates to methods and compositions for editing an ASS1 polynucleotide, e.g., an ASS1 polynucleotide comprising a SNP associated with Citrullinemia Type 1. The invention also relates to methods and compositions for treating or preventing Citrullinemia Type 1 in a subject.
    Type: Application
    Filed: November 14, 2022
    Publication date: August 17, 2023
    Inventors: Matthew Jarpe, Mallikarjuna Reddy Putta, Andrew Fraley
  • METHODS AND COMPOSITIONS FOR THE ADAR-MEDIATED EDITING OF OTOFERLIN (OTOF)
    Publication number: 20230212569
    Abstract: The present invention relates to methods and compositions for editing an OTOF polynucleotide, e.g., an OTOF polynucleotide comprising a SNP associated with autosomal recessive non-syndromic hearing loss. The invention also relates to methods and compositions for treating or preventing autosomal recessive non-syndromic hearing loss in a subject.
    Type: Application
    Filed: November 14, 2022
    Publication date: July 6, 2023
    Inventors: Matthew Jarpe, Mallikarjuna Reddy Putta, Andrew Fraley
  • Methods and Compositions for the ADAR-Mediated Editing of ABCA4
    Publication number: 20230174989
    Abstract: The present invention relates to methods and compositions for editing an ABCA4 polynucleotide, e.g., an ABCA4 polynucleotide comprising a SNP associated with Stargardt Disease, type 1. The invention also relates to methods and compositions for treating or preventing Stargardt Disease, type 1, in a subject.
    Type: Application
    Filed: May 14, 2021
    Publication date: June 8, 2023
    Applicant: Korro Bio, Inc.
    Inventors: Andrew Fraley, Mallikarjuna Reddy Putta, Matthew Jarpe
  • Antibodies to the Human Prolactin Receptor
    Publication number: 20070269438
    Abstract: This invention provides antibodies to the prolactin receptor, particularly the human prolactin receptor. Preferred antibodies are capable of blocking prolactin binding to the prolactin receptor, inhibiting signaling through the prolactin receptor, and/or inhibiting proliferation of cancer cells induced by prolactin. Also provided are nucleic acids encoding the antibodies, vectors and host cells comprising the nucleic acids, and uses of the antibodies and nucleic acids.
    Type: Application
    Filed: October 4, 2006
    Publication date: November 22, 2007
    Inventors: Brian Elenbaas, Matthew Jarpe, Steven Miklasz, Stephen Fawell